Mineral metabolism disorders in Chronic kidney disease

JAMA

Volumn 305, Issue 11, 2011, Pages 1138-1139

  Kestenbaum, Bryan ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

CALCIUM BLOOD LEVEL; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; EDITORIAL; HUMAN; MEDICAL RECORD REVIEW; META ANALYSIS (TOPIC); METABOLIC DISORDER; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS;

EID: 79952614879     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.339     Document Type: Editorial

References (15)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-2047. (Pubitemid 350074801)
2. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38. (Pubitemid 44967731)
3. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003;14(9)(suppl 4):S300-S304. (Pubitemid 37052394)
4. Neunteufl T, Katzenschlager R, Abela C, et al. Impairment of endothelium-independent vasodilation in patients with hypercalcemia. Cardiovasc Res. 1998;40(2):396-401. (Pubitemid 28506051)
5. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238. (Pubitemid 34787360)
6. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305(11):1119-1127.
7. el-Hajj Fuleihan G, Klerman EB, Brown EN, et al. The parathyroid hormone circadian rhythm is truly endogenous - a general clinical research center study. J Clin Endocrinol Metab. 1997;82(1):281-286.
8. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70(2):345-350. (Pubitemid 44086584)
9. Hruska K, Slatopolsky E. Disorders of phosphorous, calcium, and magnesium metabolism. In: Schrier R, Gottschalk C, eds. Diseases of the Kidney. Vol 3. London, England: Little, Brown, and Co; 1996:2477-2526.
10. Jüppner H, Wolf M, Salusky IB. FGF-23: more than a regulator of renal phosphate handling? J Bone Miner Res. 2010;25(10):2091-2097.
11. Kestenbaum B, Glazer NL, Köttgen A, et al. Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol. 2010;21(7):1223-1232.
12. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
13. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545-2552.
14. Ware JH. The limitations of risk factors as prognostic tools. N Engl JMed. 2006;355(25):2615-2617. (Pubitemid 44969120)
15. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4)(suppl 3):S1-S201.